Arcus Biosciences said on Friday it would stop a late-stage study testing its experimental cancer drug combination in patients with advanced stomach and esophageal cancers after it failed to improve ...

Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead Sciences-partnered cancer regimen failed.

For a time, the company looked like a high-upside growth stock. However, that story was put to the test in December, when Arcus announced the cancellation of its Phase 3 STAR-221 research due to ...

Arcus Biosciences said it will discontinue a late-stage trial for its potential cancer treatment due to futility. The study, which was being conducted in partnership with Gilead Sciences, aimed to ...

With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give Merck’s Welireg a run for its money in kidney cancer. In the phase 1/1b ...

Arcus senilis is when the cornea of your eye has a white or gray ring or arc around it. Your cornea is the transparent outer covering of your eye. It’s also known as corneal arcus. It’s common in ...

Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies HAYWARD, Calif., January 21, ...

A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Arcus Biosciences presents a high-risk speculation with significant upcoming catalysts, despite recent stock declines and Gilead's exit from the ARC-10 trial. Gilead's continued investment and board ...

Arcus senilis is a white, gray, or blue arc or ring that develops around the edge of the cornea. It typically appears as an arc that affects the top and bottom of the cornea. According to the American ...

Four Phase 3 and two Phase 2 trials are now enrolling to evaluate domvanalimab-based combinations in lung and gastrointestinal cancers. The third dose-escalation cohort (100mg) of ARC-20 for AB521, a ...